RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Cell"
DOI: 10.1016/j.ccell.2019.05.015
Abstract: Summary RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after BRAF V600 and NRAS Q61. Here, we study the role of RAC1P29S in melanoma development and reveal that RAC1P29S activates… read more here.
Keywords: melanoma; mesenchymal phenotypic; rac1p29s; resistance ... See more keywords
Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1119498
Abstract: Recurrent neoepitopes are cancer-specific antigens common among groups of patients and therefore ideal targets for adoptive T cell therapy. The neoepitope FSGEYIPTV carries the Rac1P29S amino acid change caused by a c.85C>T missense mutation, which… read more here.
Keywords: cell; neoepitope; high affinity; rac1p29s ... See more keywords